methyl (4R)-4-[(3R,5S,7R,10S,13S,14S)-3,7-bis(methoxymethoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxopentanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: methyl (4R)-4-[(3R,5S,7R,10S,13S,14S)-3,7-bis(methoxymethoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxopentanoate
• 化学式: C₂₉H₄₆O₇
• 分子量: 506.7
• InChiKey: PYDYVMVWIRXSMC-MJTIMUMASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• ROR gamma modulators
  申请人：ETH Zurich

  公开号：EP2781217A1

  公开（公告）日：2014-09-24

  The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, characterized in that at least one of R8, R9, R10 is -ORa; for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.

  本发明涉及式 I 化合物或其药学上可接受的盐、 其特征在于，R8、R9、R10 中至少有一个是-ORa；用于治疗或预防、抑制或改善由 ROR γ 受体介导的疾病，特别是糖尿病和糖尿病相关疾病，尤其是 II 型糖尿病，其生产方法，以及治疗或预防此类疾病的方法。
• ROR GAMMA MODULATORS
  申请人：ETH ZÜRICH

  公开号：US20160287609A1

  公开（公告）日：2016-10-06

  The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, characterized in that at least one of R 8 , R 9 , R 10 , R 11 is —OR a ; for use in the treatment or prevention, suppression or amelioration of a disease mediated, by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, their use as a dietary supplement or functional food, as well as methods of treatment or prevention of such diseases.